ArticleNature cancer2025
A cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinoma.
Abstract read
In one paragraph
Article in Nature cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Article
- Identification of a novel signature for prognostic stratification and integrative analyses in lung adenocarcinoma.Translational cancer research · 2026Article
- Cellular hallmarks and aging clock of the human lung parenchyma.Nature communications · 2026Article
- Functional Depth Biomarkers Distinguish Lung Squamous Cell Carcinoma from Lung Adenocarcinoma.Research square · 2026Article
- Fundamentals and emerging frontiers in p53-targeted drug development.Biochemistry and biophysics reports · 2026Review
- Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma.Journal for immunotherapy of cancer · 2026Article
- Regulatory T-cell Sensing of Extracellular ATP via P2RX7 Promotes Their Accumulation and Suppression and Drives Lung Tumor Growth.Cancer immunology research · 2026Article
- Trojan Horse Strategy: How Biomimetic Nanomedicine Remodels the Tumor Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- SPP1+ Macrophages and the Orchestration of Spatially Organized Immunosuppression in Cancer.Biomedicines · 2026Review
- Histological transformation into pulmonary sarcomatoid carcinoma from lung adenosquamous carcinoma after radical resection of EGFR gene Exon-21 L858R mutation: a case report and literature review.Frontiers in oncology · 2026Article
- Integrated CT Radiomics and Circulating Tumor Cell Analysis in Predicting Lung Adenocarcinoma Invasion: A Dual-Center Study with Implications for Personalized Treatment.OncoTargets and therapy · 2026Article
- Loss of inducible nitric oxide synthase promotes Kras/Pten-driven lung tumorigenesis.Frontiers in cell and developmental biology · 2026Article
- A cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinoma.Nature cancer · 2025Article
- Hypoxia drives shared and distinct transcriptomic changes in two invasive glioma stem cell lines.Scientific reports · 2024Article
- Pan-Cancer Integrative Analyses Reveal the Crosstalk Between the Intratumoral Microbiome, TP53 Mutation and Tumour Microenvironment.IET systems biologyArticle
Corrections and comments
- Update of
Authors and funding
33 authors.
William Zhao *Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Thinh T Nguyen *Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Atharva Bhagwat *Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0009-0004-7311-0283
Akhil Kumar *Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-8338-4203
Bruno Giotti *Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Benjamin KepecsDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jason L WeiratherDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Navin R MahadevanDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Asa SegerstolpeKlarman Cell Observatory, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Komal DolasiaDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jamshid Abdul-GhafarDepartment of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-6575-8870
Naomi R BessonCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Stephanie M JonesCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Brian Y SoongDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-4647-7704
Chendi LiMassachusetts General Hospital Cancer Center, Charlestown, MA, USA.
Sebastien VigneauCenter for Cancer Genomics, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Michal SlyperKlarman Cell Observatory, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Isaac WakiroCenter for Cancer Genomics, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Mei-Ju SuCenter for Cancer Genomics, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Karla HelvieCenter for Cancer Genomics, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Allison FrangiehCenter for Cancer Genomics, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Judit Jane-ValbuenaKlarman Cell Observatory, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Orr AshenbergKlarman Cell Observatory, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Mark AwadLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Asaf RotemCenter for Cancer Genomics, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Raphael BuenoDepartment of Thoracic Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Orit Rozenblatt-RosenKlarman Cell Observatory, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-6313-3570
Kathleen PfaffCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Scott RodigDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Aaron N HataMassachusetts General Hospital Cancer Center, Charlestown, MA, USA.ORCID http://orcid.org/0000-0002-6127-318X
Aviv RegevKlarman Cell Observatory, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-3293-3158
Bruce E JohnsonCenter for Cancer Genomics, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Alexander M TsankovDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. alexander.tsankov@mssm.edu.ORCID http://orcid.org/0000-0002-7955-4414
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MMOUNT SINAI MEDICAL SCIENTIST TRAINING PROGRAMT32GM007280 · NIGMS · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI BARON, MARGARET H · 1985 to 2021
$22.8MThe Cellular Geography of Therapeutic Resistance in CancerU2CCA233195 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2018 to 2023
$13.7MTargeting the immunologic vulnerabilities of small cell lung carcinomaK08CA270077 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Navin Mahadevan · 2022 to 2026
$1.0MTargeting MCL-1 dependent apoptotic vulnerability of KRAS-LKB1 NSCLCF32CA250231 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI LI, CHENDI · 2020 to 2022
$225kAmerican Cancer Society (American Cancer Society, Inc.) Research Scholar Grant RSG-23-1039063-01-MMNCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003INCI NIH HHS K08 CA270077NCI NIH HHS P30 CA008748NCI NIH HHS U2C CA233195NIGMS NIH HHS T32 GM007280United States Department of Defense | U.S. Army (United States Army) Lung Cancer Research Program Career Development Award W81XWH2210079U.S. Department of Health & Human Services | National Institutes of Health (NIH) 2T32GM007280-41U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) F32CA250231U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) 1T32GM146636
Abstract
Tumor protein p53 (TP53) is the most frequently mutated gene across many cancers and is associated with shorter overall survival in lung adenocarcinoma (LUAD). Here, to define how TP53 mutations affect the LUAD tumor microenvironment (TME), we constructed a multiomic cellular and spatial atlas of 23 treatment-naive human lung tumors. We found that TP53-mutant malignant cells lose alveolar identity and upregulate highly proliferative and entropic gene expression programs consistently across LUAD tumors from resectable clinical samples, genetically engineered mouse models, and cell lines harboring a wide spectrum of TP53 mutations. We further identified a multicellular tumor niche composed of SPP1
Indexed as
Adenocarcinoma of LungLung NeoplasmsTumor MicroenvironmentTumor Suppressor Protein p53AnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceMutationTP53 protein, humanTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.